Wei Hu

List of Publications by Year
in descending order

39 papers	1,281 citations	361413 20 h-index	361022 35 g-index
40 all docs	40 docs citations	40 times ranked	2784 citing authors

#	Article	IF	Citations
1	Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nature Communications, 2017, 8, 310.	12.8	169
2	FABP4 as a key determinant of metastatic potential of ovarian cancer. Nature Communications, 2018, 9, 2923.	12.8	151
3	Molecular Biomarkers of Residual Disease after Surgical Debulking of High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2014, 20, 3280-3288.	7.0	80
4	Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer. Clinical Cancer Research, 2016, 22, 1713-1724.	7.0	69
5	Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction. Cancer Research, 2018, 78, 3233-3242.	0.9	69
6	Notch3 Pathway Alterations in Ovarian Cancer. Cancer Research, 2014, 74, 3282-3293.	0.9	59
7	Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget, 2017, 8, 96496-96505.	1.8	49
8	Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer. Clinical Cancer Research, 2015, 21, 448-459.	7.0	48
9	The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Research, 2018, 7, 326.	1.6	47
10	Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth. Molecular Cancer Therapeutics, 2016, 15, 1344-1352.	4.1	41
11	Arsenic concentrations, diversity and co-occurrence patterns of bacterial and fungal communities in the feces of mice under sub-chronic arsenic exposure through food. Environment International, 2020, 138, 105600.	10.0	41
12	XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A. Clinical Cancer Research, 2015, 21, 3286-3297.	7.0	37
13	Antitumor and Antiangiogenic Effects of Aspirin-PC in Ovarian Cancer. Molecular Cancer Therapeutics, 2016, 15, 2894-2904.	4.1	37
14	Clodronate inhibits tumor angiogenesis in mouse models of ovarian cancer. Cancer Biology and Therapy, 2014, 15, 1061-1067.	3.4	34
15	Differential Effects of EGFL6 on Tumor versus Wound Angiogenesis. Cell Reports, 2017, 21, 2785-2795.	6.4	32
16	Pan–cancer clinical and molecular analysis of racial disparities. Cancer, 2020, 126, 800-807.	4.1	25
17	Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression. Gynecologic Oncology, 2019, 154, 524-530.	1.4	24
18	The Construction and Analysis of the Aberrant lncRNA-miRNA-mRNA Network in Adipose Tissue from Type 2 Diabetes Individuals with Obesity. Journal of Diabetes Research, 2020, 2020, 1-14.	2.3	24

#	Article	IF	Citations
19	ADH1B promotes mesothelial clearance and ovarian cancer infiltration. Oncotarget, 2018, 9, 25115-25126.	1.8	24
20	*PRKRA*/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	4.1	23
21	Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biology and Therapy, 2020, 21, 147-156.	3.4	21
22	Clinical significance of homologous recombination deficiency score testing in endometrial Cancer. Gynecologic Oncology, 2021, 160, 777-785.	1.4	21
23	*PTEN* Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer. Molecular Cancer Therapeutics, 2015, 14, 1466-1475.	4.1	20
24	CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance. Cell Reports, 2021, 36, 109549.	6.4	20
25	Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecologic Oncology, 2017, 147, 41-46.	1.4	17
26	Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer. Clinical Cancer Research, 2014, 20, 2740-2750.	7.0	14
27	GnRH-R–Targeted Lytic Peptide Sensitizes *BRCA* Wild-type Ovarian Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2019, 18, 969-979.	4.1	12
28	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Scientific Reports, 2019, 9, 17589.	3.3	12
29	Analysis of Heavy Metal Contamination of Agricultural Soils and Related Effect on Population Health—A Case Study for East River Basin in China. International Journal of Environmental Research and Public Health, 2020, 17, 1996.	2.6	10
30	Transient receptor potential vanilloid 4 channels as therapeutic targets in diabetes and diabetes-related complications. Journal of Diabetes Investigation, 2020, 11, 757-769.	2.4	10
31	Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells. IScience, 2020, 23, 101289.	4.1	9
32	MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecologic Oncology, 2021, 163, 181-190.	1.4	5
33	Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. Journal of Cancer Research and Clinical Oncology, 2021, 147, 3545-3555.	2.5	5
34	Targeting CCR2+ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2022, 148, 803.	2.5	5
35	Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer. Molecular Cancer Therapeutics, 2018, 17, 464-473.	4.1	4
36	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecologic Oncology, 2021, 161, 104-112.	1.4	4

#	Article	IF	Citations
37	Therapeutic efficacy of liposomal Grb2 antisense oligodeoxynucleotide (L-Grb2) in preclinical models of ovarian and uterine cancer. Oncotarget, 2020, 11, 2819-2833.	1.8	4
38	Association between Single-nucleotide Polymorphisms of RXRG and Genetic Susceptibility to Type 2 Diabetes in South China. Current Molecular Medicine, 2020, 20, 408-414.	1.3	3
39	Building a circular RNA centered gene regulation network associated with cervical squamous cell carcinoma. Epigenomics, 2020, 12, 1883-1898.	2.1	0